Tender detail
Open-house biologics discount agreements 2025-19 – adalimumab
Summary
The participating health insurers intend to conclude discount agreements for the active substance adalimumab with all suitable pharmaceutical companies. The agreements use uniform terms, involve no individual negotiations and provide no exclusivity. The term is up to 24 months from 1 August 2025 and ends no later than 31 July 2027, regardless of when an agreement is signed.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.